Stocktoria
Schrodinger, Inc. SDGR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-02-06
Schrodinger, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 55.7% | 63.6% | 64.9% | 55.8% | 47.6% |
| Operating margin | -65.2% | -100.8% | -81.9% | -81.1% | -80.8% |
| Net margin | -40.4% | -90.2% | 18.8% | -82.4% | -72.8% |
| FCF margin | 4.9% | -79.3% | -69.3% | -70.6% | -56.4% |
| Return on assets | -14.2% | -22.7% | 5.1% | -21.7% | -13.3% |
| Return on equity | -28.4% | -44.4% | 7.4% | -33.3% | -18.0% |
| Current ratio | 2.75 | 3.31 | 4.25 | 4.91 | 6.85 |
| Revenue growth | 23.3% | -4.2% | 19.7% | 31.2% | 27.6% |
Source: SEC EDGAR filings · CIK 0001490978 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.